DOI: https://doi.org/10.24959/cphj.17.1443

Ways to improve the therapy of escerichosis in children infected with Epstein-Barr virus

Ye. S. Olkhovsky

Abstract


Pathogenic escherichia in young children remains one of the main factors of bacterial lesions of the gastrointestinal tract.
Aim. To study the effectiveness of the use of interferons in the treatment of escherichiosis in children infected with Epstein-Barr virus (EBV).
Materials and methods. At the premises of the Regional Children Infectious Clinical Hospital of Kharkiv a comparison of dynamics of the clinical and laboratory parameters of 68 children aged 1-3 years old with a moderate form of escherichiosis and infected with EBV (inactive persistent form) was performed. The first group consisted of 47 children whose treatment was carried out according to the generally accepted schemes; the second group was 21 children receiving recombinant interferon alfa-2 in the complex therapy in the age-related doses twice a day for 5 days.
Results. Significant difference within the time of fever preservation (4.73±0.37 versus 3.25 ± 0.21 days, p<0.01) and disappearance of the general intoxication symptoms (4.02 ± 0.29 vs. 2.24 ± 0.35, p<0.01) were determined. According to the ultrasound study normalization of defecation (5.91 ± 0.22 vs. 4.34 ± 0.29 days, p<0.01) and elimination of signs of the parenchymal liver reaction (5.94 ± 0.39 vs. 4.15 ± 0.50 days, p<0.05), as well as mezadenite phenomena (8.67 ± 0.86 vs. 6.19 ± 0.77 days, respectively, p<0.05) were statistically significant in children of the first group. The positive effect of interferon therapy on the parameters of the clinical blood analysis was manifested in the faster normalization of the amount of leukocytes and ESR (7.55 ± 0.61 vs. 5.44 ± 0.48 days, p<0.05). In general, duration of patient’s staying at hospital in children of the first group was 10.64 ± 0.53 days, while in the second group it was 8.09 ± 0.36 days, p<0.01.
Conclusions. The use of recombinant interferon alfa-2 in the complex therapy of escherichiosis in children infected with EBV positively affects the regression of clinical manifestations, accelerates normalization of the laboratory and instrumental indices, and reduces duration of patient’s staying at hospital.


Keywords


escherihiosis; Epstein-Barr virus; children; treatment

Full Text:

PDF

References


Pronko, N. V., Danilevich, N. A., Koniuk, L. A. (2014). Zhurnal Grodnenskogo gosudarstvennogo meditcinskogo universiteta, 3, 92–95.

Pronko, N. V. Tcyrkunov, V. M., Yakusevich, T. V. (2016). Aktualnaia infektologiia, 3, 100–105.

Croxen, M. A., Law, R. J., Scholz, R., Keeney, K. M., Wlodarska, M., Finlay, B. B. (2013). Recent Advances in Understanding Enteric Pathogenic Escherichia coli. Clinical Microbiology Reviews, 26 (4), 822–880. doi: 10.1128/cmr.00022–13

WHO : The top 10 causes of death (2014). Fact sheet ¹ 310. Available at: http://www.who.int/mediacentre/factshee ts/fs310/en/

Hold, G. L., Mukhopadhya, I., Monie, T. P. (2011). Innate Immune Sensors and Gastrointestinal Bacterial Infections. Clinical and Developmental Immunology, 2011, 1–11. doi: 10.1155/2011/579650

Bolis, V., Karadedos, C., Chiotis, I., Chaliasos, N., Tsabouri, S. (2016). Atypical manifestations of Epstein–Barr virus in children: a diagnostic challenge. Jornal de Pediatria, 92 (2), 113–121. doi:10.1016/j.jped.2015.06.007

Tyunyaeva, N., Sofronova, L. (2014). Infectious Mononucleosis: Etiological Factors, Diagnosis and Treatment Problems. Journal of New Medical Technologies, 21 (3), 184–191. doi:10.12737/5932

Klimova, R. R. (2014). Pediatriia, 93 (1), 32–37.

Kasymova, E. B., Bashkina, O. A., Galimzianov, H. M. (2016). Novaia nauka: sovremennoe sostoianie i puti razvitiia 98 (8), 16–20.

Barycheva, L. Yu., Golubeva, M. V., Volkova, A. V. (2014). Detskie infektcii, 2, 28–33.

Order № 354, 09.07.2004 «On approval of protocols for diagnosis and treatment of infectious diseases in children». Available at: http://mozdocs.kiev.ua/view.php?id=3292

Simovanian, E. N. (2016). Detskie infektcii, 1 (15), 15–23.

Bulgakova, V. A. (2014). Zdorove rebenka, 2, 78–84.

Shtro, A. A., Slita, A. V., Carpinskaia, L. A. et al. (2012). Interferon activity in combination with antioxidants against DNA and RNA–containing Human viruses. Lechashchii vrach, 10, 22–26.

Gorelov, A. V., Alimova, I. L., Antonova, T. I., Feklisova, L. V. et al. (2015). Interferon preparations in therapy of acute respiratory viral infections and flu in newborns and infants. Lechashchii vrach, 1, 7–14.


GOST Style Citations


1.         Пронько, Н. В. Эпидемиологические и клинические особенности синдрома острой диареи у детей / Н. В. Пронько, Н. А. Данилевич, Л. А. Конюк // Журн. Гродненского государственного медицинского университета. – 2014. – № 3. – С. 92–95.

2.         Пронько, Н. В. К вопросу об особенностях течения энтерогеморрагического и других эшерихиозов / Н. В. Пронько, В. М. Циркунов, Т. В. Якусевич // Актуальная инфектол. – 2016. – № 3. – С. 100–105.

3.         Recent advances in understanding enteric pathogenic Escherichia coli / A. M. Croxen [et al.] // Clinical microbiol. rev. – 2013. – Vol. 26, Issue 4. – P. 822–880. doi: 10.1128/cmr.00022–13

4.         WHO : The top 10 causes of death / Fact sheet ¹ 310. – 2014. – Available at : http://www.who.int/mediacentre/factshee ts/fs310/en/

5.         Hold, G. Innate Immune Sensors and Gastrointestinal Bacterial Infections / G. Hold, L. I. Mukhopadhya, T. P. Monie // Clinical and Developmental Immunol. –2011. – Vol. 2011. – P. 1–11. doi: 10.1155/2011/579650

6.         Atypical manifestations of Epstein–Barr virus in children : a diagnostic challenge / V. Bolis [et al.] // J. de Pediatria. – 2016. – Vol. 92, Issue 2. – P. 113–121. doi: 10.1016/j.jped.2015.06.007

7.         Tyunyaeva, N. O. Infectious mononucleosis: etiological factors, diagnosis and treatment problems / N. O. Tyunyaeva, L. V. Sofronova // J. of New Medical Technol. – 2014. – Vol. 21, Issue 3. – P. 184–191. doi: 10.12737/5932

8.         Климова, Р. Р. Частота обнаружения маркеров герпесвирусных инфекций у часто болеющих детей с острой респираторной инфекцией / Р. Р. Климова // Педиатрия. – 2014. – T. 93, № 1. – С. 32–37.

9.         Касымова, Е. Б. Особенности иммунного статуса и факторы риска хронического течения Эпштейна-Барра вирусной инфекции у детей / Е. Б. Касымова, О. А. Башкина, Х. М. Галимзянов // Новая наука : современное состояние и пути развития. – 2016. – Т. 98, № 8. – С. 16–20.

10.       Барычева, Л. Ю. Факторы и механизмы иммуносупрессии при Эпштейна-Барра вирусной инфекции / Л. Ю. Барычева, М. В. Голубева, А. В. Волкова // Детские инфекции. – 2014. – № 2. – С. 28–33.

11.       Order № 354, 09.07.2004 «On approval of protocols for diagnosis and treatment of infectious diseases in children». Available at : http://mozdocs.kiev.ua/view.php?id=3292

12.       Симованьян, Э. Н. Эпштейна-Барра вирусная инфекция у детей : современные программы диагностики и лечения / Э. Н. Симованьян // Детские инфекции. – 2016. – Т. 1, № 15. – С. 15–23.

13.       Булгакова, В. А. Противовирусная терапия острых респираторных инфекций у детей / В. А. Булгакова // Здоровье ребенка. – 2014. – № 2. – С. 78–84.

14.       Interferon activity in combination with antioxidants against DNA and RNA–containing Human viruses / A. A. Shtro, A. V. Slita, L. A. Carpinskaia et al. // Лечащий врач. – 2012. – № 10. – С. 22–26.

15.       Interferon preparations in therapy of acute respiratory viral infections and flu in newborns and infants / A. V. Gorelov, I. L. Alimova, T. I. Antonova et al. // Лечащий врач. – 2015. – № 1. – С. 7–14.





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Klìn. farm.

ISSN 2518-1572 (Online), ISSN 1562-725X (Print)